[Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2].
D000818:Animals; D001011:Aorta / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D001161:Arteriosclerosis / Q000473:pathology; D001241:Aspirin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D004036:Diet, Atherogenic; D011464:Epoprostenol / Q000096:biosynthesis*; D008239:Lysine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits
D002995:Clofibric Acid; C016894:plafibride; D011464:Epoprostenol; D002994:Clofibrate; D008239:Lysine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate
Valoración del efecto del plafibride y del acetil salicilato de lisina en la producción de PGI2.